VTN

VTN Full Name

vitronectin

VTN Introduction

Vitronectin (VTN) is a multifunctional glycoprotein abundant in plasma and the extracellular matrix, and it has gained increasing attention as a critical regulator of the extracellular microenvironment rather than a passive structural component. For researchers and translational scientists struggling to connect coagulation, tissue repair, and immune regulation into a unified framework, vitronectin offers a compelling anchor point. It exists in both a 75 kDa single-chain form and a processed two-chain form (65 + 10 kDa), with functional domains such as the somatomedin B (SMB) domain and heparin-binding regions that enable broad molecular interactions. These structural features underlie its indispensable role in early blood coagulation events, particularly platelet adhesion and aggregation, as well as fibrinolysis control through interactions with plasminogen activator inhibitor-1 (PAI-1). By stabilizing clots while simultaneously orchestrating wound healing and extracellular matrix remodeling, vitronectin functions as a master coordinator at the interface of hemostasis, inflammation, and tissue regeneration—an area where many therapeutic strategies still lack integrative biomarkers or targets.

From a disease relevance perspective, vitronectin has emerged as more than a background plasma protein, addressing a common pain point in clinical research: the need for reliable, mechanism-linked biomarkers. Recent clinical studies have shown that circulating vitronectin levels are significantly elevated in patients with gestational diabetes mellitus, with strong positive correlations to fasting glucose, postprandial glucose, and HbA1c. This positions vitronectin as a promising predictive and monitoring biomarker for metabolic dysregulation during pregnancy, a field where early detection remains challenging. Beyond metabolic disease, vitronectin is increasingly implicated in chronic degenerative conditions such as osteoarthritis. Mechanical overload at the osteochondral interface has been shown to induce vitronectin upregulation, suggesting that it participates in mechanotransduction pathways that influence chondrocyte stiffness sensing, extracellular matrix mineralization, and cartilage degeneration. These findings resonate with researchers seeking to understand how biomechanical stress translates into molecular signals driving disease progression.

Vitronectin's functional reach also extends into host–pathogen interactions and immune evasion, highlighting its relevance for infectious disease and immunology research. Certain pathogens, including avian bacteria such as Riemerella anatipestifer, exploit vitronectin by binding it via specific outer membrane proteins to evade complement-mediated killing. This ability to hijack a host complement regulatory factor underscores vitronectin's central role in immune defense while revealing a vulnerability that pathogens can manipulate. Importantly, this cross-species functionality reinforces the concept of vitronectin as a conserved immune modulator rather than a species-specific factor. For scientists and developers looking for targets that bridge coagulation, immunity, metabolism, and mechanobiology, vitronectin represents a biologically rich and clinically relevant molecule with growing diagnostic and therapeutic potential, supported by emerging evidence across diverse disease contexts.

Alternate Names for VTN

VTN; vitronectin; VN; V75; VNT; epibolin; S-protein; somatomedin B; complement S-protein; serum spreading factor; serum-spreading factor;

• 1.Pliego-Arreaga R, et al.; Joint Hypermobility Syndrome and Membrane Proteins: A Comprehensive Review. Biomolecules. 2024, 14(4):472.
  2.Ozgen L, et al.; Role of increased plasminogen activator inhibitor-1 and vitronectin in gestational diabetes mellitus. Rev Assoc Med Bras (1992). 2023, 69(9):e20230563.